Disclosed is a pharmaceutical composition comprisingi) a dopamine agonist andii) a L-DOPA derivativein combination in form of a liquid preparation.The pharmaceutical composition comprises a dopamine agonist selected from the group comprising apomorphine, ropinirole, rotigotine, pramipexole, and piribedile and a L-DOPA derivative selected from L-DOPA, selectively and/ or partially deuterated L-DOPA derivatives, as well as physiologically acceptable salts of the aforementioned L-DOPA derivatives.The pharmaceutical composition is provided in a form of a parental application selected from infusions, injections or an application via a gastric tube.The pharmaceutical composition is used for the treatment of Parkinsons disease, of restless leg syndrome, of dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormones, for the treatment of neurological symptoms of chronic manganese intoxication, of amyotrophic lateral scleroses and of multiple system atrophy.
